Phase 1 Transverse Myelitis Trial, Recruiting NCT06620809 Sponsor: Tongji Hospital Condition: Transverse Myelitis
Back to Transverse Myelitis

Phase 1 Transverse Myelitis Trial, Recruiting

NCT06620809
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) based on recognised international criteria, and you have tested positive for a specific protein marker called AQP4 antibodies.
  • Your current symptoms started within the last 7 days, and you are experiencing severe pain, weakness in your legs, or problems with bladder or bowel control.
  • You are between 18 and 65 years old (male or female).
  • Before this current episode, your level of disability was relatively low, as measured by a standard disability scale used in this condition (confirm with trial site).
  • If you are a woman who could become pregnant, you must have a negative pregnancy test at the start of the trial and agree to use effective contraception throughout.
  • You (or your legal representative) are willing and able to give signed consent to take part.

Who may not be able to join:

  • Your blood test results show certain abnormalities, such as low counts of white blood cells, red blood cells, or platelets, or signs that your kidneys or liver are not working well (confirm with trial site for specific values).
  • You have a medical reason that prevents you from having a lumbar puncture (a procedure to collect fluid from around your spine).
  • You are currently pregnant, breastfeeding, or planning to become pregnant during the trial.
  • You have a known allergy to biological products made from human sources, or you are generally prone to allergies.
  • You have previously had a stem cell transplant or radiation therapy targeting your lymphatic system.
  • You have taken part in another clinical trial in the last 3 months.
  • You have a serious condition affecting your immune system or your blood's ability to clot.
  • You have had active thoughts of suicide in the last 6 months, or you have attempted suicide in the last 3 years.
  • You have severe psychiatric symptoms that would make it difficult to participate in the trial.
  • You have a current problem with alcohol addiction or drug misuse.
  • You have or have had a malignant tumour (cancer).
  • In the last 12 weeks, you have had a heart attack, unstable heart disease, a stroke, or severe heart failure.
  • You currently have an ongoing widespread infection or a serious localised infection.
  • You are unable to have MRI scans during the trial.
  • The trial doctor considers you unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dai-shi Tian, MD, Tongji Hospoital

Phone: 86-27-83663337

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Tongji Hospital
Registry
ClinicalTrials.gov
Start date
28 March 2025
Est. completion
30 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence and severity of all adverse events (AE) and serious adverse events (SAE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov